Open an account

Lakewood-Amedex Biotherapeutics

LABT · NASDAQ

$0.5775+$0.0002 (+0.03%)TodayMarket closed ·
Prev close $0.5773

About LABT

Lakewood-Amedex Biotherapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in University Park, Florida and currently employs 5 full-time employees. The company went IPO on 2026-04-23. Lakewood-amedex Biotherapeutics Inc is a pharmaceutical company. The firm is focused on addressing unmet needs in the treatment of serious infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, NDM-1, and many others. The firm is engaged in development of its Bisphosphocin class of antimicrobial agents. The firm is exploring additional local drug delivery applications, including complicated urinary tract infections (CAUTI) and pulmonary infections. The firm has a portfolio of compounds that are being profiled for indications such as infected diabetic foot ulcer, urinary tract infections, and pulmonary infections.

Employees
5
Headquarters
University Park, Florida
Listed
Apr 23, 2026
Sector
Health Care
Industry
Biotechnology
Website
lakewoodamedex.com

LABT key statistics

Market cap
1.37M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
643.24K
Volume
568
Open price
$0.5879
High today
$0.6204
Low today
$0.57
52 Week high
$98.20
52 Week low
$0.56

Lakewood-Amedex Biotherapeutics (LABT) at a glance

Lakewood-Amedex Biotherapeutics (LABT) last traded at $0.5775, with a market cap of 1.37M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.57 and $0.6204. The current price is 1.3% above the day's low and 6.9% below its high.

Volume so far is 568 shares, below the average of 643.24K shares a day.

Over the past year Lakewood-Amedex Biotherapeutics has ranged from $0.56 to $98.20, and now sits 0% of the way up that range.

LABT news

  • Press releasePRNewswire

    Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds

  • Press releasePRNewswire

    Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences

  • Press releasePRNewswire

    Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers

  • Vandana Singh

    Beyond Antibiotics: Lakewood-Amedex Advances Diabetic Foot Ulcer Trial

  • Press releasePRNewswire

    Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

  • Press releasePRNewswire

    Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3

  • Press releasePRNewswire

    Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

  • Press releasePRNewswire

    Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Similar companies

Companies in the same industry as Lakewood-Amedex Biotherapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.